Michael James Mcclellan - Net Worth and Insider Trading

Michael James Mcclellan Net Worth

The estimated net worth of Michael James Mcclellan is at least $279,010 dollars as of 2025-05-13. Michael James Mcclellan is the EVP, CFO of Teva Pharmaceutical Industries Ltd and owns about 15,898 shares of Teva Pharmaceutical Industries Ltd (TEVA) stock worth over $279,010. Details can be seen in Michael James Mcclellan's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Michael James Mcclellan has not made any transactions after 2019-11-05 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Michael James Mcclellan

Michael James Mcclellan Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Michael James Mcclellan owns 1 companies in total, including Teva Pharmaceutical Industries Ltd (TEVA) .

Click here to see the complete history of Michael James Mcclellan’s form 4 insider trades.

Insider Ownership Summary of Michael James Mcclellan

Ticker	Company	Transaction Date	Type of Owner
TEVA	Teva Pharmaceutical Industries Ltd	2019-11-05	EVP & Chief Financial Officer

Michael James Mcclellan Latest Holdings Summary

Michael James Mcclellan currently owns a total of 1 stock. Michael James Mcclellan owns 15,898 shares of Teva Pharmaceutical Industries Ltd (TEVA) as of November 5, 2019, with a value of $279,010.

Latest Holdings of Michael James Mcclellan

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
TEVA	Teva Pharmaceutical Industries Ltd	2019-11-05	15,898	17.55	279,010

Holding Weightings of Michael James Mcclellan

Michael James Mcclellan Form 4 Trading Tracker

According to the SEC Form 4 filings, Michael James Mcclellan has made a total of 0 transactions in Teva Pharmaceutical Industries Ltd (TEVA) over the past 5 years. The most-recent trade in Teva Pharmaceutical Industries Ltd is the sale of 242 shares on November 5, 2019, which brought Michael James Mcclellan around $2,137.

Insider Trading History of Michael James Mcclellan

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Michael James Mcclellan Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Michael James Mcclellan Ownership Network

Ownership Network List of Michael James Mcclellan

No Data

Ownership Network Relation of Michael James Mcclellan

Michael James Mcclellan Owned Company Details

What does Teva Pharmaceutical Industries Ltd do?

Who are the key executives at Teva Pharmaceutical Industries Ltd?

Michael James Mcclellan is the EVP & Chief Financial Officer of Teva Pharmaceutical Industries Ltd. Other key executives at Teva Pharmaceutical Industries Ltd include EVP & Global Human Resources Mark Sabag , Exec. VP & European Commercial Richard Daniell , and President and CEO Richard D Francis .

Teva Pharmaceutical Industries Ltd (TEVA) Insider Trades Summary

Over the past 18 months, Michael James Mcclellan made no insider transaction in Teva Pharmaceutical Industries Ltd (TEVA). Other recent insider transactions involving Teva Pharmaceutical Industries Ltd (TEVA) include a net sale of 475,266 shares made by Richard Daniell , a net sale of 100,893 shares made by Eric A Hughes , and a net sale of 615,541 shares made by Mark Sabag .

In summary, during the past 3 months, insiders sold 663,030 shares of Teva Pharmaceutical Industries Ltd (TEVA) in total and bought 0 shares, with a net sale of 663,030 shares. During the past 18 months, 2,523,753 shares of Teva Pharmaceutical Industries Ltd (TEVA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 2,523,753 shares.

Teva Pharmaceutical Industries Ltd (TEVA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Teva Pharmaceutical Industries Ltd Insider Transactions

No Available Data

Michael James Mcclellan Mailing Address

Above is the net worth, insider trading, and ownership report for Michael James Mcclellan. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Michael James Mcclellan's mailing address is: Petach Tikva L3 4951033.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.